Janet Dawson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9390987/publications.pdf Version: 2024-02-01

		361413	434195
32	1,619	20	31
papers	citations	h-index	g-index
32	32	32	2928
all docs	docs citations	times ranked	citing authors

IANET DAWSON

#	Article	IF	CITATIONS
1	GPR91 senses extracellular succinate released from inflammatory macrophages and exacerbates rheumatoid arthritis. Journal of Experimental Medicine, 2016, 213, 1655-1662.	8.5	337
2	Serum Amyloid A (apoSAA) Expression Is Up-Regulated in Rheumatoid Arthritis and Induces Transcription of Matrix Metalloproteinases. Journal of Immunology, 2001, 166, 2801-2807.	0.8	141
3	Targeting monocyte chemoattractant protein-1 signalling in disease. Expert Opinion on Therapeutic Targets, 2003, 7, 35-48.	3.4	126
4	Deficiency of MALT1 Paracaspase Activity Results in Unbalanced Regulatory and Effector T and B Cell Responses Leading to Multiorgan Inflammation. Journal of Immunology, 2015, 194, 3723-3734.	0.8	123
5	Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase. Journal of Medicinal Chemistry, 2020, 63, 5102-5118.	6.4	92
6	A natural ligand for the orphan receptor GPR15 modulates lymphocyte recruitment to epithelia. Science Signaling, 2017, 10, .	3.6	76
7	Macrophage infiltration into the rat knee detected by MRI in a model of antigen-induced arthritis. Magnetic Resonance in Medicine, 2003, 49, 1047-1055.	3.0	69
8	Fluorescent Nanoprobes as a Biomarker for Increased Vascular Permeability: Implications in Diagnosis and Treatment of Cancer and Inflammation. Bioconjugate Chemistry, 2010, 21, 93-101.	3.6	63
9	Pharmacological inhibition of RORγt suppresses the Th17 pathway and alleviates arthritis in vivo. PLoS ONE, 2017, 12, e0188391.	2.5	54
10	Anti-hyperalgesic activity of the cox-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat. Pain, 2004, 107, 33-40.	4.2	46
11	The critical role of kinase activity of interleukinâ€1 receptor–associated kinase 4 in animal models of joint inflammation. Arthritis and Rheumatism, 2009, 60, 1661-1671.	6.7	46
12	Retinoic-acid-orphan-receptor-C inhibition suppresses Th17 cells and induces thymic aberrations. JCI Insight, 2017, 2, e91127.	5.0	46
13	The monoclonal antibody MEL-14 can block lymphocyte migration into a site ofchronic inflammation. European Journal of Immunology, 1992, 22, 1647-1650.	2.9	41
14	High-resolution three-dimensional magnetic resonance imaging for the investigation of knee joint damage during the time course of antigen-induced arthritis in rabbits. Arthritis and Rheumatism, 1999, 42, 119-128.	6.7	37
15	In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4719-4723.	2.2	30
16	CYCLOSPORIN A INHIBITS THE IN VIVO PRODUCTION OF INTERLEUKIN- 1^2 AND TUMOUR NECROSIS FACTOR $\hat{1}_{\pm}$, BUT NOT INTERLEUKIN-6, BY A T-CELL-INDEPENDENT MECHANISM. Cytokine, 1996, 8, 882-888.	3.2	29
17	Transient targeting of phosphoinositide 3-kinase acts as a roadblock in mast cells' route to allergy. Journal of Allergy and Clinical Immunology, 2013, 132, 959-968.	2.9	29
18	Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors. Scientific Reports, 2017, 7, 13591.	3.3	28

JANET DAWSON

#	Article	IF	CITATIONS
19	Synthesis and Biological Evaluation of New Triazolo―and Imidazolopyridine RORγt Inverse Agonists. ChemMedChem, 2016, 11, 2640-2648.	3.2	26
20	Nondepleting anti-CD4 and soluble interleukin-1 receptor prevent autoimmune destruction of syngeneic islet grafts in diabetic NOD mice1. Transplantation, 2002, 74, 611-619.	1.0	25
21	Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A ₄ Hydrolase. Journal of Medicinal Chemistry, 2021, 64, 1889-1903.	6.4	23
22	Optimizing a Weakly Binding Fragment into a Potent RORÎ ³ t Inverse Agonist with Efficacy in an in Vivo Inflammation Model. Journal of Medicinal Chemistry, 2018, 61, 6724-6735.	6.4	22
23	Design and synthesis of potent and orally active GPR4 antagonists with modulatory effects on nociception, inflammation, and angiogenesis. Bioorganic and Medicinal Chemistry, 2017, 25, 4512-4525.	3.0	20
24	Pathophysiological Consequences of a Break in S1P1-Dependent Homeostasis of Vascular Permeability Revealed by S1P1 Competitive Antagonism. PLoS ONE, 2016, 11, e0168252.	2.5	17
25	Targeting interleukin-4 to the arthritic joint. Journal of Controlled Release, 2020, 326, 172-180.	9.9	17
26	Structure-Based and Property-Driven Optimization of <i>N</i> -Aryl Imidazoles toward Potent and Selective Oral RORγt Inhibitors. Journal of Medicinal Chemistry, 2019, 62, 10816-10832.	6.4	15
27	Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation. ACS Medicinal Chemistry Letters, 2019, 10, 1467-1472.	2.8	15
28	Inhibition of the Inositol Kinase Itpkb Augments Calcium Signaling in Lymphocytes and Reveals a Novel Strategy to Treat Autoimmune Disease. PLoS ONE, 2015, 10, e0131071.	2.5	15
29	Could rheumatoid arthritis have an infectious aetiology?. Drug Discovery Today Disease Mechanisms, 2005, 2, 345-349.	0.8	5
30	Degenerative joint disease induced by repeated intra-articular injections of monosodium urate crystals in rats as investigated by translational imaging. Scientific Reports, 2022, 12, 157.	3.3	4
31	Nonhematopoietic IRAK1 drives arthritis via neutrophil chemoattractants. JCI Insight, 2022, 7, .	5.0	2
32	Cantharidinâ€Induced Skin Blister as an In Vivo Model of Inflammation. Current Protocols, 2021, 1, e49.	2.9	0